AtaiBeckley Secures Key U.S. Patent for EMP-01 Psychedelic Therapy, Extending Exclusivity Through 2043
核心洞察
AtaiBeckley (搜索) received U.S. Patent No. 12,492,178 covering EMP-01 (oral R-MDMA), providing exclusivity through 2043 for this novel mental health treatment.
The patent protects a highly-crystalline, thermodynamically stable HCl salt form of R-MDMA with enhanced pharmaceutical properties for manufacturing and storage.
EMP-01 is currently in Phase 2a trials for social anxiety disorder, with topline data expected in Q1 2026, addressing an unmet need affecting 18 million Americans.
AtaiBeckley (搜索) N.V. (NASDAQ: ATAI) announced that the United States Patent and Trademark Office has granted a new patent covering EMP-01 (oral R-MDMA), strengthening the company's intellectual property portfolio for its novel mental health treatment program. The patent, No. 12,492,178, is expected to provide exclusivity through 2043 and covers critical drug substance attributes of the psychedelic therapy candidate.
Patent Strengthens Commercial Position
The newly granted patent includes claims to the drug substance of EMP-01 and identifies a highly-crystalline, thermodynamically stable HCl salt form of (R)-MDMA with high aqueous solubility and low hygroscopicity. These form-specific attributes provide benefits during formulation development, drug product manufacture, and storage of both drug substance and drug product.
"This patent grant reinforces the strength of our science and our long-term commitment to building durable, defensible innovation," stated Srinivas Rao, M.D., Ph.D., Chief Executive Officer and Co-founder of AtaiBeckley (搜索). "EMP-01 is an important asset in our pipeline, and securing this patent issuance in the U.S. further strengthens our ability to advance the program while delivering meaningful value for patients and shareholders."
Clinical Development Progress
EMP-01 is an oral formulation of R-3,4-methylenedioxy-methamphetamine (R-MDMA) that demonstrated a unique, dose-dependent subjective effect profile in a Phase 1 trial. The compound was generally found to be more similar to classical psychedelics than to racemic MDMA in its effects profile.
The company is currently enrolling patients into an exploratory, randomized, double-blind, placebo-controlled Phase 2 study to assess the safety, tolerability and efficacy of EMP-01 in adults with social anxiety disorder (SAD). Topline data from the exploratory Phase 2a study is anticipated in the first quarter of 2026.
Addressing Significant Unmet Medical Need
Social anxiety disorder represents an area of high unmet medical need, with approximately 18 million people currently diagnosed in the United States. No novel molecules have been approved for this indication in over two decades, highlighting the potential significance of EMP-01's development program.
Anxiety disorders are the most common mental health disorders worldwide, affecting how individuals experience worry, fear and anxiety in everyday situations. The development of EMP-01 supports AtaiBeckley (搜索)'s strategy to develop innovative, differentiated therapies designed to address significant unmet needs in mental health.
Expanding Patent Portfolio
AtaiBeckley (搜索) continues to expand its global patent portfolio across its pipeline to support clinical development, potential commercialization, and strategic flexibility as the company advances its mission to create new breakthroughs in mental health. The company was formed through the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited in November 2025.
The clinical-stage biopharmaceutical company's pipeline includes multiple novel therapies in Phase 2 clinical development, including BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression, VLS-01 (buccal film DMT) for treatment-resistant depression, and EMP-01 for social anxiety disorder.